Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1347

1.

JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.

Delbue S, Elia F, Carloni C, Pecchenini V, Franciotta D, Gastaldi M, Colombo E, Signorini L, Carluccio S, Bellizzi A, Bergamaschi R, Ferrante P.

J Neurovirol. 2014 Jul 23. [Epub ahead of print]

PMID:
25052191
[PubMed - as supplied by publisher]
2.

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.

Agnihotri SP, Dang X, Carter JL, Fife TD, Bord E, Batson S, Koralnik IJ.

Neurology. 2014 Jul 18. pii: 10.1212/WNL.0000000000000713. [Epub ahead of print]

PMID:
25037207
[PubMed - as supplied by publisher]
3.

Moving to fingolimod from natalizumab in multiple sclerosis-reply.

Cohen M, Lebrun C.

JAMA Neurol. 2014 Jul 1;71(7):925. doi: 10.1001/jamaneurol.2014.1138. No abstract available.

PMID:
25023556
[PubMed - in process]
4.

Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved.

Bianco A, Rossini PM, Mirabella M.

JAMA Neurol. 2014 Jul 1;71(7):924-5. doi: 10.1001/jamaneurol.2014.1135. No abstract available.

PMID:
25023553
[PubMed - in process]
5.

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.

Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, McGuiness CB, Korn JR.

J Med Econ. 2014 Jul 23:1-12. [Epub ahead of print]

PMID:
25019581
[PubMed - as supplied by publisher]
6.

Nervous system viral infections in immunocompromised hosts.

Pruitt AA.

Handb Clin Neurol. 2014;123:685-704. doi: 10.1016/B978-0-444-53488-0.00034-1.

PMID:
25015512
[PubMed - in process]
7.

Progressive multifocal leukoencephalopathy.

Berger JR.

Handb Clin Neurol. 2014;123:357-76. doi: 10.1016/B978-0-444-53488-0.00017-1.

PMID:
25015495
[PubMed - in process]
8.

Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.

Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, Gasperini C, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group.

Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):147-54.

PMID:
25004826
[PubMed - in process]
9.

Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies.

Pellegrino P, Carnovale C, Perrone V, Pozzi M, Antoniazzi S, Radice S, Clementi E.

Vaccine. 2014 Jul 5. pii: S0264-410X(14)00869-X. doi: 10.1016/j.vaccine.2014.06.068. [Epub ahead of print] Review.

PMID:
25000592
[PubMed - as supplied by publisher]
10.

No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.

Capobianco M, di Sapio A, Malentacchi M, Malucchi S, Matta M, Sperli F, Bertolotto A.

Eur J Neurol. 2014 Jul 3. doi: 10.1111/ene.12487. [Epub ahead of print]

PMID:
24995482
[PubMed - as supplied by publisher]
11.

[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].

[No authors listed]

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):65-9. Russian.

PMID:
24988963
[PubMed - in process]
12.

Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data.

Carroll CA, Fairman KA, Lage MJ.

BMC Health Serv Res. 2014 Jul 2;14(1):286. [Epub ahead of print]

PMID:
24986083
[PubMed - as supplied by publisher]
Free Article
13.

An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab.

Sánchez Gomar I, Díaz Sánchez M, Uclés Sánchez AJ, Casado Chocán JL, Ramírez-Lorca R, Serna A, Villadiego J, Toledo-Aral JJ, Echevarría M.

BMC Neurol. 2014 Jul 1;14(1):139. doi: 10.1186/1471-2377-14-139.

PMID:
24980919
[PubMed - in process]
Free PMC Article
14.

Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?

Stüve O, Cutter GR.

JAMA Neurol. 2014 Jun 30. doi: 10.1001/jamaneurol.2014.1201. [Epub ahead of print] No abstract available.

PMID:
24979690
[PubMed - as supplied by publisher]
15.

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.

JAMA Neurol. 2014 Jun 30. doi: 10.1001/jamaneurol.2014.1200. [Epub ahead of print]

PMID:
24977406
[PubMed - as supplied by publisher]
16.

The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.

O'Connell KE, Mok T, Sweeney B, Ryan AM, Dev KK.

Autoimmunity. 2014 Jun 30:1-7. [Epub ahead of print]

PMID:
24974887
[PubMed - as supplied by publisher]
17.

Minimal supportive treatment in natalizumab-related PML in a MS patient.

Lalive PH, Bridel C, Ferfoglia RI, Kaiser L, Du Pasquier R, Barkhof F, Haller S.

J Neurol Neurosurg Psychiatry. 2014 Jun 23. pii: jnnp-2014-308154. doi: 10.1136/jnnp-2014-308154. [Epub ahead of print] No abstract available.

PMID:
24957322
[PubMed - as supplied by publisher]
18.

Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study.

Mancuso R, Franciotta D, Rovaris M, Caputo D, Sala A, Hernis A, Agostini S, Calvo M, Clerici M.

Mult Scler. 2014 Jun 16. pii: 1352458514538111. [Epub ahead of print]

PMID:
24948690
[PubMed - as supplied by publisher]
19.

Severe anemia in a patient with multiple sclerosis treated with natalizumab.

Simone AM, Ferraro D, Vitetta F, Marasca R, Bonacorsi G, Pinelli G, Federzoni L, Nichelli PF, Sola P.

Neurology. 2014 Jul 22;83(4):374-5. doi: 10.1212/WNL.0000000000000614. Epub 2014 Jun 18. No abstract available.

PMID:
24944259
[PubMed - in process]
20.

Natalizumab: risk stratification of individual patients with multiple sclerosis.

Tur C, Montalban X.

CNS Drugs. 2014 Jul;28(7):641-8. doi: 10.1007/s40263-014-0168-0.

PMID:
24942634
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk